Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
Not Confirmed
Not Confirmed
30 September-02 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Industry Trade Show
Not Confirmed
30 September-02 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
30 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/30/2920713/0/en/Anaveon-appoints-Dieter-Weinand-as-Chair-of-its-Board-of-Directors.html
29 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/29/2889543/0/en/Anaveon-announces-IND-approval-of-ANV600-001-EXPAND-Phase-I-II-clinical-study.html
23 Mar 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/03/23/2632845/0/en/Anaveon-announces-presentation-of-a-novel-development-compound-at-the-2023-American-Association-for-Cancer-Research-Annual-Meeting.html
16 Mar 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/03/16/2628317/0/en/Anaveon-announces-first-patient-dosed-with-ANV419-in-a-Phase-I-II-Study-of-ANV419-in-patients-with-multiple-myeloma.html
02 Feb 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/02/02/2600164/0/en/Anaveon-doses-first-patient-in-a-Phase-I-II-Study-of-ANV419-as-monotherapy-or-in-combination-with-check-point-inhibitors-in-patients-with-advanced-melanoma.html
09 Sep 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/09/10/2513542/0/en/Anaveon-presents-updated-data-from-the-Phase-I-II-study-of-ANV419-during-the-ESMO-Congress-2022.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?